Cargando…

Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture

Natural killer cell engagers gained enormous interest in recent years due to their potent anti-tumor activity and favorable safety profile. Simultaneously, chicken-derived antibodies entered clinical studies paving the way for avian-derived therapeutics. In this study, we describe the affinity matur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bogen, Jan P., Carrara, Stefania C., Fiebig, David, Grzeschik, Julius, Hock, Björn, Kolmar, Harald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141644/ https://www.ncbi.nlm.nih.gov/pubmed/34040611 http://dx.doi.org/10.3389/fimmu.2021.669496

Ejemplares similares

Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody
por: Harwardt, Julia, et al.
Publicado: (2023)

Expeditious Generation of Biparatopic Common Light Chain Antibodies via Chicken Immunization and Yeast Display Screening
por: Bogen, Jan P., et al.
Publicado: (2020)

Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies
por: Carrara, Stefania C., et al.
Publicado: (2022)

Recombinant Antibody Production Using a Dual-Promoter Single Plasmid System
por: Carrara, Stefania C., et al.
Publicado: (2021)

TriTECM: A tetrafunctional T-cell engaging antibody with built-in risk mitigation of cytokine release syndrome
por: Carrara, Stefania C., et al.
Publicado: (2022)

Streamlining the Transition From Yeast Surface Display of Antibody Fragment Immune Libraries to the Production as IgG Format in Mammalian Cells
por: Fiebig, David, et al.
Publicado: (2022)

A Generic Strategy to Generate Bifunctional Two-in-One Antibodies by Chicken Immunization
por: Harwardt, Julia, et al.
Publicado: (2022)

Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics
por: Bogen, Jan P., et al.
Publicado: (2021)

Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy
por: Au, Kin Man, et al.
Publicado: (2020)

Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers
por: Cheng, Ying, et al.
Publicado: (2020)

Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2022)

Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2023)

Dual Function pH Responsive Bispecific Antibodies for Tumor Targeting and Antigen Depletion in Plasma
por: Bogen, Jan P., et al.
Publicado: (2019)

Cancer therapeutic trispecific antibodies recruiting both T and natural killer cells to cancer cells
por: Kimura, Kouki, et al.
Publicado: (2023)

A trispecific killer engager molecule against CLEC12A effectively induces NK cell mediated killing of AML cells
por: Arvindam, Upasana Sunil, et al.
Publicado: (2020)

Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma
por: Abrams, R. E., et al.
Publicado: (2022)

Generation of a host cell line containing a MAR‐rich landing pad for site‐specific integration and expression of transgenes
por: Oliviero, Claudia, et al.
Publicado: (2022)

Structural insights and biomedical potential of IgNAR scaffolds from sharks
por: Zielonka, Stefan, et al.
Publicado: (2014)

Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy
por: Ravirala, Divya, et al.
Publicado: (2021)

Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression
por: Ding, Ziqiang, et al.
Publicado: (2023)

A novel IgG Fc by computer-aided design enhances heavy-chain heterodimerization in bi- or trispecific antibodies
por: Wang, Bo, et al.
Publicado: (2022)

When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2023)

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants
por: Rothenberger, Sylvia, et al.
Publicado: (2022)

Vom Huhn abgeleitete Antikörper für Diagnostik und Immuntherapie
por: Elter, Adrian, et al.
Publicado: (2021)

Specific Targeting of Lymphoma Cells Using Semisynthetic Anti-Idiotype Shark Antibodies
por: Macarrón Palacios, Arturo, et al.
Publicado: (2020)

Grabbing the Bull by Both Horns: Bovine Ultralong CDR-H3 Paratopes Enable Engineering of ‘Almost Natural’ Common Light Chain Bispecific Antibodies Suitable For Effector Cell Redirection
por: Klewinghaus, Daniel, et al.
Publicado: (2022)

Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins
por: Debelec-Butuner, Bilge, et al.
Publicado: (2022)

REAL-Select: Full-Length Antibody Display and Library Screening by Surface Capture on Yeast Cells
por: Rhiel, Laura, et al.
Publicado: (2014)

The impact of proline isomerization on antigen binding and the analytical profile of a trispecific anti-HIV antibody
por: Masiero, Alessandro, et al.
Publicado: (2020)

A novel one-step approach for the construction of yeast surface display Fab antibody libraries
por: Rosowski, Simon, et al.
Publicado: (2018)

Analysis of [Gossypium capitis-viridis × (G.hirsutum × G.australe)(2)] Trispecific Hybrid and Selected Characteristics
por: Chen, Di, et al.
Publicado: (2015)

Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity
por: Steinhardt, James J., et al.
Publicado: (2018)

Biophysical and biochemical characterization of a VHH-based IgG-like bi- and trispecific antibody platform
por: Pekar, Lukas, et al.
Publicado: (2020)

A Trispecific Anti-HIV Chimeric Antigen Receptor Containing the CCR5 N-Terminal Region
por: Hajduczki, Agnes, et al.
Publicado: (2020)

Semi-synthetic vNAR libraries screened against therapeutic antibodies primarily deliver anti-idiotypic binders
por: Könning, Doreen, et al.
Publicado: (2017)

Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections
por: Promsote, Wanwisa, et al.
Publicado: (2023)

Aptamers Binding to c-Met Inhibiting Tumor Cell Migration
por: Piater, Birgit, et al.
Publicado: (2015)

Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties
por: Castoldi, R., et al.
Publicado: (2012)

Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity
por: Elter, Adrian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qgc8po6v08psfrk2ej94ctkfje